Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 209,393 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright purchased 209,393 shares of the firm’s stock in a transaction dated Monday, June 23rd. The shares were bought at an average cost of $20.87 per share, with a total value of $4,370,031.91. Following the transaction, the director now directly owns 3,569,522 shares of the company’s stock, valued at approximately $74,495,924.14. This represents a 6.23% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Vera Therapeutics Stock Up 3.2%

Shares of Vera Therapeutics stock opened at $23.31 on Thursday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.77 and a beta of 1.13. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a current ratio of 27.68, a quick ratio of 27.68 and a debt-to-equity ratio of 0.10. The business’s 50 day simple moving average is $22.55 and its 200-day simple moving average is $29.23.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) earnings per share. Equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $85.00 price objective (up from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. Scotiabank reissued an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Guggenheim reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Finally, Wedbush lowered their price target on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $65.00.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors have recently modified their holdings of VERA. Rhumbline Advisers lifted its position in Vera Therapeutics by 12.5% in the 4th quarter. Rhumbline Advisers now owns 58,589 shares of the company’s stock valued at $2,478,000 after purchasing an additional 6,515 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Vera Therapeutics by 19.5% in the fourth quarter. New York State Common Retirement Fund now owns 28,822 shares of the company’s stock valued at $1,219,000 after purchasing an additional 4,709 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Vera Therapeutics by 5.9% during the fourth quarter. Bank of New York Mellon Corp now owns 141,948 shares of the company’s stock valued at $6,003,000 after buying an additional 7,895 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Vera Therapeutics by 19.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 430,665 shares of the company’s stock worth $18,213,000 after buying an additional 68,860 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Vera Therapeutics by 515.0% during the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company’s stock worth $9,949,000 after acquiring an additional 197,014 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.